CCCC
C4 Therapeutics, Inc.
$3.06
-3.77%
2026-10-23
About C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Key Fundamentals
Forward P/E
-2.99
EPS (TTM)
$-0.91
ROE
-48.1%
Revenue Growth (YoY)
2.8%
Profit Margin
-289.4%
Debt/Equity
23.00
Price/Book
1.48
Beta
2.94
Market Cap
$366.6M
Avg Volume (10D)
2.1M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$4.38
60D Low
$2.59
Avg Volume
2.3M
Latest Close
$3.06
Get breakout alerts for CCCC
Sign up for Breakout Scanner to receive daily notifications when CCCC triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
C4 Therapeutics, Inc. (CCCC) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CCCC daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CCCC operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.